Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227415 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
A Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
- 14
- Study locations
NCT07227415 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 224 participants, above the 198-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (13% higher). The trial reports 14 study locations across 11 states.
The verdict
NCT07227415, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Conditions Studied
Interventions
- BIOLOGICAL PF-08634404
- DRUG Combination 1
- DRUG Combination 2
Study Locations (14)
Texas
- Texas Oncology - Central South - Austin
- Texas Oncology - Gulf Coast - Houston
Virginia
- Virginia Cancer Specialists, PC - Fairfax
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Wytheville
Other
- National Hospital Organization Kyushu Cancer Center - Fukuoka
- Yamagata University Hospital - Yamagata
Arkansas
- Highlands Oncology Group - Springdale
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
Colorado
- Rocky Mountain Cancer Centers, LLP - Denver
Illinois
- City Of Hope - Chicago - Zion
Minnesota
- Minnesota Oncology Hematology, P.A. - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227415
The ClinicalTrials.gov registry entry for NCT07227415 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (13% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which PF-08634404 is the first listed.
NCT07227415 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Texas, Virginia, Other.
Frequently Asked Questions
What is clinical trial NCT07227415 about?
NCT07227415 is a clinical study titled "A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer". This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the ...
What is the current status of trial NCT07227415?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2026-02-10. Estimated completion is 2028-11-01.
What conditions does trial NCT07227415 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Renal Cancer, Advanced Renal Cell Carcinoma.
What interventions are being tested in trial NCT07227415?
The interventions under investigation include: PF-08634404 (BIOLOGICAL), Combination 1 (DRUG), Combination 2 (DRUG).
Who is sponsoring clinical trial NCT07227415?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227415 being conducted?
This trial has 14 study locations across Arkansas, California, Colorado, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
-
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
RECRUITING · Phase 1
Explore more on PlainTrial
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Metastatic Renal Cell Carcinoma
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.